MOTS-c

What is it?

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. Mitochondria help cells handle energy, and MOTS-c is being studied as a signal that links energy demands with metabolism. Interest focuses on insulin sensitivity, endurance, and maintaining physical function with age. [1,2]

The MOTS-c that your body produces and a manufactured peptide administered as a treatment answer different research questions. Evidence about one does not automatically establish benefits from the other.

How does it work?

Cell and mouse experiments suggest MOTS-c can influence AMPK, an enzyme involved in sensing cellular energy needs. Researchers found changes in glucose use and improved insulin sensitivity in mice. In high-fat-diet experiments, treatment also reduced weight gain. These findings provide a biological reason to study it, but they do not show that it produces fat loss or treats insulin resistance in people. [1]

What does the exercise research show?

A 2021 study included ten healthy young men who completed a cycling exercise session. Their own MOTS-c levels rose in blood and muscle afterward. The participants were not given MOTS-c. This shows that the peptide responds to exercise; it does not show that taking it improves a workout. [2]

In separate experiments in the same paper, administering MOTS-c improved treadmill performance in mice of different ages. That is promising preclinical evidence, with a substantial remaining step between a mouse endurance test and better human athletic performance. [2]

Has it been tested as a treatment in people?

A registered phase 2 study, NCT07505745, plans to compare MOTS-c with placebo in 120 adults with prediabetes and overweight or obesity over 12 weeks. As checked in October 2026, the registry lists it as recruiting and has no results posted. It therefore cannot yet establish an improvement in insulin sensitivity or safety. [3]

You may also see claims about CB4211. This modified MOTS-c analogue underwent a separate early human trial. The sponsor reported changes in exploratory metabolic markers, but CB4211 is a different molecule; those findings cannot be assigned to native MOTS-c or products sold under that name. [4]

What about safety and sport?

MOTS-c is not an FDA-approved medicine. FDA's 2026 review found no clinical treatment data sufficient to establish its effectiveness or human safety and flagged uncertainty about immune reactions and peptide quality. We did not identify published results establishing a benefit from administered native MOTS-c. [5]

MOTS-c is explicitly prohibited at all times under the 2026 World Anti-Doping Agency list. [6]